New York – Paul Hastings LLP, a leading global law firm, announced that the firm advised Phosplatin Therapeutics on a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (Merck), to evaluate a novel oncology molecule, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody.
The global strategic alliance will enable further clinical investigation across a range of tumor types, and under the terms of the collaboration, Phosplatin Therapeutics will be responsible for conducting Phase Ib/IIa clinical trials in several indications.
Phosplatin Therapeutics is a private, clinical stage pharmaceutical company located in New York, US, which holds the exclusive license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company's research and development work to date has spanned thirteen countries, and been funded by private investors and family investment offices in the United States, Europe and Asia.
The Paul Hastings team was led by Corporate partner Samuel Waxman.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.